Using controlled clinical trials to learn more about acute drug-induced liver injury
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is of major interest to hepatologists and clinicians in general, patients, government regulators, and the pharmaceutical industry. Understanding why this form of injury occurs only in certain individuals has major implications for the development and availability of drug therapies and in the prevention of these events. A single controlled clinical trial may be unlikely to show cases of such rare events, but in the aggregate, clinical trials offer a unique resource for learning more about individual susceptibility and developing truly predictive new biomarkers for DILI. We pose the question as to whether clinical trials could be modified or improved to provide data that would better answer some of the outstanding issues. At a recent (March 2008) public meeting, experts from academia, industry, and regulatory bodies discussed several major issues regarding liver safety in clinical trials including: what signals of liver injury should justify stopping administration of study drug or allowing it to continue; if deliberate rechallenge should be done and under what circumstances; whether patients with liver disease should be included in clinical trials; and what kinds of new biomarkers will be needed to answer these questions more clearly. Past clinical trials have not provided data to settle those issues, and reliance has defaulted to consensus of expert opinions. Modified and better clinical trials with standardized collection of data and biospecimens are probably the best source of new and potentially valuable information to supplant current rules based on consensus of expert opinions and to understand by what mechanisms and how to distinguish those individuals who are susceptible to severe DILI. (Hepatology 2008.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Self-citationDrug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Self-citationInsight into hepatotoxicity: The troglitazone experience†
Watkins, P. B. (2005) · Hepatology · doi:10.1002/hep.20598 · Cited by 45
Self-citation
Cited by
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
Case definition and phenotype standardization in drug-induced liver injury
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944
Self-citationAPASL ACLF Research Consortium (AARC) for APASL ACLF working Party., Sarin, S. K., Choudhury, A., Sharma, M. K., Maiwall, R., Al Mahtab, M., Rahman, S., Saigal, S., Saraf, N., Soin, A. S., et al. (2019) · Hepatology International · doi:10.1007/s12072-019-09946-3 · Cited by 884
Silver Enhances Antibiotic Activity Against Gram-Negative Bacteria
Morones-Ramirez, J. R., Winkler, J. A., Spina, C. S., & Collins, J. J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006276 · Cited by 756
Robles–Diaz, M., Lucena, M. I., Kaplowitz, N., Stephens, C., Medina–Cáliz, I., González–Jimenez, A., Ulzurrun, E., Gonzalez, A. F., Fernandez, M. C., Romero–Gómez, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.050 · Cited by 301
CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Drug-induced Liver Injury (DILI) Study Group, Yu, Y.-C., Chinese Society of Hepatology (CSH), Chinese Medical Association (CMA), Mao, Y.-M., Chen, C.-W., Chen, J.-J., Chen, J., Cong, W.-M., Ding, Y., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9793-2 · Cited by 254
Drug Safety Sciences and the Bottleneck in Drug Development
Watkins, P. B. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.63 · Cited by 211
Self-citationDrug-Induced Acute-on-Chronic Liver Failure in Asian Patients
Devarbhavi, H., Choudhury, A. K., Sharma, M. K., Maiwall, R., Al Mahtab, M., Rahman, S., Chawla, Y. K., Dhiman, R. K., Duseja, A., Taneja, S., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000201 · Cited by 85
Asnis, G. M., Bose, A., Gommoll, C. P., Chen, C., & Greenberg, W. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08197 · Cited by 83
Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000057 · Cited by 77
Bakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W. M., Liebowitz, M., & Khan, A. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130040 · Cited by 70
Niu, H., Sanabria-Cabrera, J., Alvarez-Alvarez, I., Robles-Diaz, M., Stankevičiūtė, S., Aithal, G. P., Björnsson, E. S., Andrade, R. J., & Lucena, M. I. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105404 · Cited by 58
Clarke, J. I., Dear, J. W., & Antoine, D. J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1160057 · Cited by 46
Gommoll, C. P., Greenberg, W. M., & Chen, C. (2014) · Journal of Drug Assessment · doi:10.3109/21556660.2014.884505 · Cited by 43
Roth, S. E., Avigan, M. I., Bourdet, D., Brott, D., Church, R., Dash, A., Keller, D., Sherratt, P., Watkins, P. B., Westcott‐Baker, L., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1571 · Cited by 42
Self-citationDrug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status
Shi, Q., Yang, X., Greenhaw, J. J., Salminen, A. T., Russotti, G. M., & Salminen, W. F. (2017) · International Journal of Toxicology · doi:10.1177/1091581817721675 · Cited by 37
Iruzubieta, P., Arias-Loste, M. T., Barbier-Torres, L., Martinez-Chantar, M. L., & Crespo, J. (2015) · BioMed Research International · doi:10.1155/2015/386186 · Cited by 24
(2014) · Europe PMC (PubMed Central) · Cited by 24
DILI Differences and Similarities between the US and Europe
Toro-Ortiz, J. P., Andrade, R. J., & Pinazo-Bandera, J. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00733-x
Metadata
- Authors
- Watkins, P. B., Seligman, P. J., Pears, J. S., Avigan, M. I., & Senior, J. R.
- Venue
- Hepatology
- Published
- 2008-11
- Volume
- 48
- Issue
- 5
- Pages
- 1680-1689
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2005521037
- Cited by
- 115
- References
- 8
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.